Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

Status:	Active, not recruiting
Conditions:	Lymphoma
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	11/16/2018
Start Date:	March 6, 2014
End Date:	April 8, 2019

A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Follicular Lymphoma (FL)

The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by
independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in
subjects with FL lymphoma who have failed therapy with both CD20 antibody and an alkylating
agent.

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Grade 1, 2, or 3a FL without pathologic evidence of transformation

- Male and female, ages 18 and above, with relapsed or refractory FL lymphoma after > or
=2 prior treatment lines; each of the 2 prior treatment lines must include at least
CD20 antibody and/or an alkylating agent

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1

Exclusion Criteria:

- Known central nervous system lymphoma

- History of interstitial lung disease

- Subjects with active, known or suspected autoimmune disease

- Prior allogeneic stem cell transplant

- Prior autologous stem cell transplant ≤12 weeks prior to first dose of study drug

We found this trial at

sites

Dana-Farber Cancer Institute

450 Brookline Ave
Boston, Massachusetts 2215

617-632-3000